Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 1551 to 1600 of 2490 results for term

  1. What symptoms do children, young people, pregnant women and older people with suspected post‑COVID‑19 syndrome present with?

    Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188 Date issued December

  2. The social care guidance manual (PMG10)

    This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used

  3. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  4. What is the clinical effectiveness of D-dimer and other blood tests and clinical features as prognostic markers of developing post‑COVID‑19 syndrome?

    Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188 Date issued December

  5. Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable.

  6. AI technologies for detecting diabetic retinopathy (MIB265)

    NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .

  7. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

  8. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  9. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188 Date issued December

  10. Jaundice in newborn babies under 28 days (QS57)

    This quality standard covers recognising and managing jaundice in newborn babies (neonatal jaundice), from birth to 28 days, in primary care (including community care) and secondary care. It describes high-quality care in priority areas for improvement.

  11. Phrenic nerve pacing for congenital central hypoventilation syndrome (IPG790)

    Evidence-based recommendations on phrenic nerve pacing for congenital central hypoventilation syndrome. This involves direct stimulation of the phrenic nerve, to produce the inhalation phrase of breathing.

  12. Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal (IPG642)

    Evidence-based recommendations on Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal in adults. This involves using the ileum to create a pouch on the inside of the abdominal wall to collect waste.

  13. Management of anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of CKD in people who are receiving erythropoietic stimulating agents (ESAs) and have a significant concurrent acute infectious illness?

    anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of CKD...

  14. Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

  15. Midostaurin for untreated acute myeloid leukaemia (TA523)

    Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.

  16. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.

  17. Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

    Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.

  18. Baricitinib for moderate to severe rheumatoid arthritis (TA466)

    Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.

  19. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  20. Insertion of endobronchial valves for persistent air leaks (IPG448)

    Evidence-based recommendations on insertion of endobronchial valves for treatment of persistent air leaks. This involves inserting valves into the airways to reduce or stop air leaks so the rest of the lung can function normally.

  21. Endovascular closure of atrial septal defect (IPG96)

    Evidence-based recommendations on endovascular closure of atrial septal defect. This involves inserting a small blocking device into the heart, which is gently inflated to close the hole.

  22. High dose rate brachytherapy for carcinoma of the cervix (IPG160)

    Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.

  23. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

  24. Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

    Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.

  25. Further research should be in the form of randomised controlled trials or registries. It should report:

    dysfunction details of the procedure, including the device used short- and long-term outcomes, including patient-reported outcomes....

  26. Liver disease (QS152)

    This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults. It describes high-quality care in priority areas for improvement.

  27. Home care for older people (QS123)

    This quality standard covers care and support for older people living in their own homes (known as home care or domiciliary care). It covers people aged over 65 using home care services, and may also cover some people under 65 with complex needs. It describes high-quality care in priority areas for improvement.

  28. Child abuse and neglect (QS179)

    This quality standard covers recognising, assessing and responding to abuse and neglect of children and young people under 18. It covers physical, sexual and emotional abuse. This quality standard describes high-quality care in priority areas for improvement.

  29. Sickle cell disease (QS58)

    This quality standard covers managing acute painful episodes of sickle cell disease in hospital. It includes pain relief and care for children, young people and adults, from presentation in hospital until discharge. It describes high-quality care in priority areas for improvement.

  30. Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)

    Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.

  31. Acne vulgaris: management (NG198)

    This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.

  32. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

  33. NICE encourages research into endovascular stentgrafting of popliteal aneurysms and may review this procedure on publication of further evidence.

    concerns. Evidence on efficacy is inadequate because it is limited to the short-term. Therefore this procedure should only be used with...

  34. Evidence on the safety and efficacy of midcarpal hemiarthroplasty for wrist arthritis is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of  research .

    patient-reported outcome measures and the need for revision in the longer term (at least 5 years). Source guidance details Comes from...

  35. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  36. Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe emphysema is inadequate in quantity and quality. Therefore the procedure should only be used in the context of  research .

    Further research should evaluate safety and efficacy in the short and long term and include details of patient selection. NICE may...

  37. Evidence on the safety and efficacy of high-intensity focused ultrasound for glaucoma is inadequate in quality and quantity. Therefore, this procedure should only be used in the context of  research .

    procedure with standard therapies and should report safety events and long-term outcomes. NICE may update the guidance on publication of...

  38. Percutaneous transluminal renal sympathetic denervation for resistant hypertension should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    data. It should report details of patient selection, technique used and long-term outcomes. Source guidance details Comes from guidance...

  39. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

  40. Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who have had surgery and radioactive iodine (RAI), what is the optimal duration of thyroid stimulating hormone suppression?

    made this recommendation for research, see the rationale section on long-term duration of TSH suppression. Full details of the evidence...

  41. Percutaneous balloon valvuloplasty for fetal critical aortic stenosis (IPG613)

    Evidence-based recommendations on percutaneous balloon valvuloplasty for fetal critical aortic stenosis. This involves placing a catheter into the baby’s heart, while the baby is still in the womb. The aim is to help the heart develop properly.

  42. Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor (IPG617)

    Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults. This involves applying ultrasound to a specific area on 1 side of the brain (thalamus).

  43. MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (IPG671)

    Evidence-based recommendations on MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy in adults and children. This involves inserting a laser into the area of the brain causing seizures.

  44. Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment (IPG772)

    Evidence-based recommendations on removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. This involves surgically removing ovarian tissue before a treatment for cancer or other medical condition that can damage the ovaries (gonadotoxic treatment) begins. The ovarian tissue is then frozen to be reimplanted after the gonadotoxic treatment is finished, to restore fertility.

  45. Totally endoscopic robotically assisted coronary artery bypass grafting (IPG128)

    Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB). This involves using small, remote-controlled robotic arms to carry out the grafting procedure.

  46. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

  47. Prosthetic intervertebral disc replacement in the lumbar spine (IPG306)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the lumbar spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  48. Intramedullary distraction for lower limb lengthening (IPG718)

    Evidence-based recommendations on intramedullary distraction for lower limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter leg.